Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > JDRF commits £1.3 million to investigate medication with the potential to delay kidney complications
Thanks to JDRF supporters, we’ve been able to award a £1.3 million grant to King’s College London (KCL) and Steno Diabetes Center Copenhagen to examine how existing drugs, known as SGLT inhibitors, could delay the progression of kidney disease in people living with type 1 diabetes.
While kidney complications are common in people with type 1 diabetes, there are currently no approved medications to treat kidney disease in people with the condition.
Researchers at KCL and the Steno Diabetes Center Copenhagen will study the effects of sotagliflozin, a Sodium-Glucose Co-Transporter (SGLT) inhibitor, on people with type 1 and kidney disease.
SGLT inhibitors are drugs that work by blocking the protein SGLT-2 in the kidneys. This protein usually helps the kidneys reabsorb glucose from urine that would otherwise be lost when you urinate. As a result, when SGLT is blocked, more glucose ends up in the urine and is removed from the body, helping patients with type 2 diabetes manage their condition more effectively.
Over the past decade, SGLT inhibitors have proven to be effective for people with type 2 diabetes and people without diabetes, reducing the progression of kidney disease and heart disease.
However, there has been a lack of research exploring SGLT inhibitors as a treatment for people with kidney disease and type 1 diabetes. This award from JDRF will allow the investigators to find out how this type of therapy works in type 1.
A trial will take place at the Steno Center in Copenhagen and at KCL, where clinicians will recruit participants from across southeast London. Researchers will investigate how the drug, sotagliflozin, works on the kidneys using magnetic resonance imaging (MRI), which can provide a measure of kidney function and oxygen content, as well as measure a potential benefit on the heart.
“In the past decade we have seen amazing results in the treatment of diabetes complications with the drug class SGLT inhibitors. They have reduced progression of kidney and heart disease in people with type 2 diabetes and improve glycemic control in type 1 diabetes, but it is not clear how they work,” said Peter Rossing, M.D., Head of Complications Research At Steno Diabetes Center Copenhagen and lead investigator for this study. “Understanding how SGLT inhibitors work is important for the optimal use of these drugs. With no current approved medication for treatment of kidney disease in people with type 1 diabetes, our study could help pave the way if a benefit is demonstrated.”
Recent work from KCL highlighted that African-Caribbean people with type 1 diabetes had a higher and faster risk of kidney disease progression, which was independent of traditional risk factors.
During this trial, researchers at KCL will have the additional aim of evaluating whether there are potential biological differences between African-Caribbean and non-African-Caribbean people in kidney baseline measures as well as in treatment responses.
Janaka Karalliedde, Clinical Reader in Diabetes and Cardiovascular Disease at King’s College London, says: “To date there are no clinical trials in people with type 1 diabetes of African-Carribean heritage who are often at higher risk of kidney complications of diabetes. This landmark study is a really important first milestone in this area and we are delighted to be involved as there is huge potential for new treatments that will make real clinical impact in an under-researched area of type 1 diabetes.”
Rachel Connor, Director of Research Partnerships at JDRF UK said: “We are delighted to provide funding for this much-needed clinical trial which will test whether SGLT-2 inhibitors can slow the progression of kidney disease in people with type 1 diabetes. Kidney disease is challenging to live with. Its treatments are demanding, it limits people’s lifestyles and it’s emotionally draining; and yet there are currently no approved medicines for people with type 1 diabetes and kidney disease.
“If this study shows that SGLT-2 inhibitors can effectively delay kidney complications for people with type 1, the results could be put into practice very swiftly, benefiting the entire type 1 diabetes community, enabling people to live longer, healthier and happier lives.”
People with type 1 diabetes are at a higher risk of developing kidney problems, called nephropathy.<br />
New research confirms for the first time that ethnicity is a risk factor for developing kidney disease in people with type 1 diabetes.
We’ve written a letter to Gillian Keegan MP, Secretary of State for Education, asking her to make exemptions to the Government’s policy on banning mobile phones in schools. We thought you might like to read it.
As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.
Insulet, the company who make Omnipod® products, has announced that their Omnipod® 5 hybrid closed loop (HCL) technology is now available in the UK.
Immunotherapy, beta cell replacement, smart insulins – we’re driving research in the most promising areas to find cures and better treatments for type 1 diabetes.
